NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...
Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its primary and a key secondary endpoint in the phase III NIMBLE trial of ...
WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve ...
PHOENIX – Generalized myasthenia gravis patients had dramatically lower incidence of flares and crises after starting on the complement component 5 inhibitor eculizumab (Soliris), data from a ...
Zilucoplan is a subcutaneous, self-administered, macrocyclic peptide inhibitor of complement component 5. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
Credit: Shutterstock. Zilucoplan is a synthetic, macrocyclic peptide inhibitor of complement component 5. Positive topline results were announced from a phase 3 study evaluating the efficacy and ...
In the version of this article initially published, the numbers in the 'R sym ' row in Table 1 are in the wrong columns. The error has been corrected in the HTML and ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced positive topline results from its Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results